Navigation Links
Delcath Signs First Partner Agreement in Asia
Date:2/9/2010

NEW YORK, Feb. 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. ( DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System  (the Delcath PHP System™).  The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore. 

Under terms of the agreement, Chi-Fu will fund and manage clinical studies at up to four sites to gather data for submission to Taiwan government regulatory agencies for approval.  Any regulatory filings will be in the name of Delcath Systems, Inc.  For the clinical studies, Chi-Fu will purchase, at a discount, Delcath PHP Systems to treat up to 200 patients with hepatic cancer.  Any additional systems required will be sold at a confidential distributor price.  It is intended that at least two of the clinical study sites will become reference sites when the studies are completed. 

Under the terms of the agreement, Delcath is to receive $1 million in milestone payments, comprised of $300,000 upon execution of the agreement and the balance upon receipt of the CE Mark and upon receipt of FDA approval. In addition Chi-Fu will be contractually committed to purchase a minimum number of systems annually during the term of the agreement, commencing when commercial sales begin in Taiwan. The term of th
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic ... clinical trial of SG2000 in ovarian cancer.  The trial ... of the USA, and is now actively recruiting patients ... will evaluate the overall response rate of SG2000 in ...
... (NYSE: AZN ) today announced that ... extended the time to complete its review of ... (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO) (Logo: ... Prescription Drug User Fee Act (PDUFA) date from ...
Cached Medicine Technology:Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 2Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 3U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application 2
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... 9, 2014 There has been a sharp increase ... Medical Center using MyChart, the online, interactive service that ... with their healthcare providers, schedule appointments, and renew prescriptions. ... actively using MyChart each year increased five-fold, ... more than 10-fold, according to a study by ...
(Date:7/9/2014)... around the world have been linked to an ... from the National Institute for Mathematical and Biological ... also contribute. , In a series of ... severe hemorrhage of internal organs in frogs, could ... if they are exposed to the virus every ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2
... August 16, 2011 Seattle Children,s Research Institute ... million grant from the Bill & Melinda Gates ... respiratory support device, called Seattle Children,s Positive Airway ... affordable and simple Bubble Continuous Positive Airway Pressure ...
... Italy, August 16, 2011 Facial expressions convey strong ... interpret these cues is crucial in social interaction. This ... and neurological disorders, such as social anxiety or Korsakoff,s ... stress disorder (PTSD) is also characterized by changes in ...
... 16 (HealthDay News) -- Many women in the United States ... due to dangerous ingredients, a new study indicates. Pai ... which are banned in the United States because they increase ... U.S. Food and Drug Administration announced a recall of Pai ...
... exercise routine means being able to overcome the obstacles ... the confidence that you can do it, researchers report. ... abilities increase this "situation-specific self-confidence," a quality the researchers ... self-efficacy to every single health behavior you can think ...
... 15 (HealthDay News) -- You might want to take a ... researchers report that alcohol hinders the restorative functions of sleep. ... students, appear online and in the November print issue of ... Booze,s effect on sleep appears linked to a disruption ...
... , MONDAY, Aug. 15 (HealthDay News) -- ,Just 15 ... death by 14 percent and increase your life expectancy by three ... to do at least 150 minutes, or a total of 1.5 ... finds that doing even half that -- 15 minutes daily is ...
Cached Medicine News:Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 2Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 3Health News:Reduced recognition of fear and sadness in post-traumatic stress disorder 2Health News:U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall 2Health News:Want to keep your exercise resolutions? New research offers pointers 2Health News:Want to keep your exercise resolutions? New research offers pointers 3Health News:More Evidence That Alcohol Hinders Good Sleep 2Health News:A Little Exercise Goes a Long Way to Cut Disease, Death Risk 2
... a two-level control compatible with popular ... Strips and Roche Micral test strips. ... turbidimetric immunoassays using AU Series, Bayer ... Cobas, Diasorin SPQ Test System, Dimension, ...
... the performance of Abuscreen ONLINE, AxSYM, EMIT, ... methods. This control meets current revised guidelines ... Health Services Administration (SAMSHA). Level 1 is ... analytes below screening cut-off levels (negative threshold ...
... 190 spectrophotometer is ideal for most life ... solutions, our patented* PathCheck sensor technology senses ... microplate well, and normalizes the absorbance value ... is within 5% of the value obtained ...
... This control is intended as a ... testing methods. A new feature is ... CRP. It is compatible with most ... ACS:180, Access, Dimension, Elecsys, Stratus and ...
Medicine Products: